HOLD — Catalyst-Anchored, Architecture-Defined, Alpha-Bleed Acknowledged
HOLD is the calibrated synthesis position: it rejects aggressive deployment (front-running a falling knife without reversal confirmation), rejects the Research Manager's 30-35% trim (overcalibrated multiplier per 10/05 reflection when catalyst has not fired with expected asymmetry), rejects full Sell (transferring alpha risk without realizing breakdown payoff per 9/16 precedent), and rejects further underweight trimming (capitulation at $123.73 below prior trim levels). The 4.71% yield carry, 14.1x forward multiple, and 93-year dividend history provide floor characteristics; the Q3 print is the binding catalyst that breaks the regime. If the print confirms the bear cluster, the pre-committed Underweight/Sell escalation executes. If the print clears with constructive surprise, the pre-committed Overweight upgrade executes. The alpha cost of waiting is bounded by the catalyst itself, not indefinite patience.
| Position | Action |
|---|---|
| Pre-Q3 print (current) | Maintain current residual (50-60% of original from 9/29 trim); no new capital deployment |
| Post-Q3 print triggers engage (upgrade confirmation) | Cap new exposure at 1.5% portfolio |
| Q3 print confirms bear cluster (miss, soft guide, GLP-1 disclosure) | Trim 25-30% of residual; tighten stop to $118 |
PepsiCo is a high-quality compounder temporarily re-rated downward to a level where the dividend yield exceeds earnings risk, creating a value entry into a defensive fortress with a deeply oversold technical setup that historically precedes mean reversion.
| Indicator | Value | Signal |
|---|---|---|
| close_10_ema | 126.85 | bearish |
| close_50_sma | 135.30 | bearish |
| close_200_sma | 144.25 | bearish |
| macd | -3.21 | bearish |
| macds | -2.82 | bearish |
| macdh | -0.39 | bearish |
| rsi | 22.20 | bearish |
| vwma | 128.03 | bearish |
Support: 121.81 | Resistance: 126.85 · 128.03 · 135.3 · 144.25
Technical analysis shows PEP trading at $123.73 with price below all three moving averages (10 EMA: 126.85, 50 SMA: 135.30, 200 SMA: 144.25) in a unanimous bearish alignment. The MACD triplet is deeply negative (MACD: -3.21, signal: -2.82, histogram: -0.39) with momentum expanding to the downside. RSI at 22.20 is deeply oversold but shows no bullish divergence yet. Volume of 13,263,972 confirms distribution, and price below VWMA ($128.03) confirms the downtrend. The 12% decline from $140.69 (Aug 26) to current levels represents a trend failure pattern, not a shallow dip. Key resistance at $126.85/$128.03; support at $123.47 and $121.81 (Bollinger lower band).
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Beat but no raise + flat Frito-Lay commentary
Then: Maintain Hold; reassess after call commentary settles 24-48 hours
↩ rebuts: “bear's trend continuation thesis”
EV: +9% · concedes: Trend is currently down; Trends almost never turn on a single data point; GLP-1 drugs are a structural concern (though company actively adapting); Dollar strength creates short-term FX translation headwinds
PEP is being correctly de-rated by the market as a structurally slower-growth business with a leverage-funded dividend, hostile macro conditions (4%+ yields competing with 4.71% yield), and no technical reversal triggers present — making the risk-reward negative at current levels.
EV: -$2.85 to -$4.85 per share (negative) · concedes: Oversold conditions CAN precede bounces; The spring may eventually decompress
→ vs conservative: Conservative plan to wait for RSI divergence confirmation means missing 8-12% of upside as stock typically rallies before higher low forms
→ vs conservative: A-rated balance sheet, 93-year dividend history, 0.36 beta, and FCF covering dividends contradicts 'evidentiary support' for market skepticism
→ vs conservative: 10-year at 4.7% (23-year highs) does not stay elevated forever; when it breaks lower, this defensive name will be first rotation target
→ vs neutral: Waiting for 50 SMA reclaim at 135.30 (9.4% rally needed) means watching 9-10% upside pass by, then only deploying 50% of intended position
→ vs neutral: Traders' 1.5% portfolio cap with three confirmation triggers before deployment dramatically worsens expected value vs. establishing position now
Market Cap
$169.02 B
TTM PE Ratio
16.22×
Forward PE
13.89×
PEG Ratio
1.29
Price to Book
7.65×
EPS (TTM)
$7.63
Forward EPS
$8.91
Dividend Yield
4.71%
Beta
0.364
52-Week High
$171.48
52-Week Low
$123.47
50-Day MA
$136.49
200-Day MA
$147.01
Revenue FY2022
$86.39 B
Revenue FY2023
$91.47 B
Revenue FY2024
$91.85 B
Revenue FY2025
$93.93 B
Cost of Revenue FY2022
$40.58 B
Cost of Revenue FY2023
$41.88 B
Cost of Revenue FY2024
$41.74 B
Cost of Revenue FY2025
$43.07 B
Gross Profit FY2022
$45.82 B
Gross Profit FY2023
$49.59 B
Gross Profit FY2024
$50.11 B
Gross Profit FY2025
$50.86 B
SG&A FY2022
$34.46 B
SG&A FY2023
$36.68 B
SG&A FY2024
$37.19 B
SG&A FY2025
$37.37 B
Operating Income FY2022
$11.36 B
Operating Income FY2023
$12.91 B
Operating Income FY2024
$12.92 B
Operating Income FY2025
$13.49 B
EBITDA FY2022
$14.92 B
EBITDA FY2023
$15.75 B
EBITDA FY2024
$16.68 B
EBITDA FY2025
$15.54 B
Net Income FY2022
$8.91 B
Net Income FY2023
$9.07 B
Net Income FY2024
$9.58 B
Net Income FY2025
$8.24 B
Diluted EPS FY2022
$6.42
Diluted EPS FY2023
$6.56
Diluted EPS FY2024
$6.95
Diluted EPS FY2025
$6.00
Cash & Equivalents FY2022
$5.35 B
Cash & Equivalents FY2023
$10.00 B
Cash & Equivalents FY2024
$9.27 B
Cash & Equivalents FY2025
$9.53 B
Total Current Assets FY2022
$21.54 B
Total Current Assets FY2023
$26.95 B
Total Current Assets FY2024
$25.83 B
Total Current Assets FY2025
$27.95 B
Goodwill & Intangibles FY2022
$33.79 B
Goodwill & Intangibles FY2023
$32.66 B
Goodwill & Intangibles FY2024
$32.34 B
Goodwill & Intangibles FY2025
$33.98 B
Total Assets FY2022
$92.19 B
Total Assets FY2023
$100.50 B
Total Assets FY2024
$99.47 B
Total Assets FY2025
$107.40 B
Total Current Liabilities FY2022
$26.79 B
Total Current Liabilities FY2023
$31.65 B
Total Current Liabilities FY2024
$31.54 B
Total Current Liabilities FY2025
$32.76 B
Long-Term Debt FY2022
$35.66 B
Long-Term Debt FY2023
$37.60 B
Long-Term Debt FY2024
$37.22 B
Long-Term Debt FY2025
$42.32 B
Total Debt FY2022
$39.55 B
Total Debt FY2023
$44.66 B
Total Debt FY2024
$44.95 B
Total Debt FY2025
$49.90 B
Total Liabilities FY2022
$74.91 B
Total Liabilities FY2023
$81.86 B
Total Liabilities FY2024
$81.30 B
Total Liabilities FY2025
$86.85 B
Stockholders' Equity FY2022
$17.15 B
Stockholders' Equity FY2023
$18.50 B
Stockholders' Equity FY2024
$18.04 B
Stockholders' Equity FY2025
$20.41 B
Net Debt FY2022
$34.12 B
Net Debt FY2023
$34.39 B
Net Debt FY2024
$35.80 B
Net Debt FY2025
$40.02 B
Operating Cash Flow FY2022
$10.81 B
Operating Cash Flow FY2023
$13.44 B
Operating Cash Flow FY2024
$12.51 B
Operating Cash Flow FY2025
$12.09 B
Capital Expenditures FY2022
$5.21 B
Capital Expenditures FY2023
$5.52 B
Capital Expenditures FY2024
$5.32 B
Capital Expenditures FY2025
$4.42 B
Free Cash Flow FY2022
$5.60 B
Free Cash Flow FY2023
$7.92 B
Free Cash Flow FY2024
$7.19 B
Free Cash Flow FY2025
$7.67 B
Dividends Paid FY2022
$6.17 B
Dividends Paid FY2023
$6.68 B
Dividends Paid FY2024
$7.23 B
Dividends Paid FY2025
$7.64 B
Share Repurchases FY2022
$1.50 B
Share Repurchases FY2023
$1.00 B
Share Repurchases FY2024
$1.00 B
Share Repurchases FY2025
$1.00 B
Net Business Purchases FY2022
$2.63 B
Net Business Purchases FY2023
$0.24 B
Net Business Purchases FY2024
$0.09 B
Net Business Purchases FY2025
$3.35 B
Net Debt Issuance FY2022
$0.81 B
Net Debt Issuance FY2023
$4.77 B
Net Debt Issuance FY2024
$0.70 B
Net Debt Issuance FY2025
$3.75 B
Financing Cash Flow FY2022
$8.52 B
Financing Cash Flow FY2023
$3.01 B
Financing Cash Flow FY2024
$7.56 B
Financing Cash Flow FY2025
$4.98 B
Operating Margin (TTM)
16.84%
Net Profit Margin (TTM)
10.78%
Return on Equity (TTM)
51.51%
Return on Assets (TTM)
8.93%
EBITDA Margin
19.5%
TTM Revenue
$96.90 B
4-Year Revenue CAGR
2.8%
Net Income TTM
$10.45 B
Net Income Change 2024 to 2025
-14.0%
Impairment Charge FY2025
$1.99 B
Net Debt/EBITDA
2.1×
Debt/Equity
239%
Current Ratio
0.93
FCF Coverage of Dividend
1.0×
Goodwill
$18.9 B
Intangibles
$15.1 B
Retained Earnings
$72.8 B
Treasury Stock
$41.8 B
Accumulated Other Comprehensive Losses
$15.0 B
Credit Rating
A/A-
Strengths
Concerns
PepsiCo is a high-quality, defensive consumer staples leader with a generous 4.71% dividend yield, fortress-like brand portfolio, and resilient cash flows. However, 2025 net income declined 14% (-$1.99B impairment charge), and elevated leverage, weak technical setup (price below 50/200-day MAs), and structural threats from health-conscious consumers and GLP-1 drugs warrant a cautious stance. The valuation (Forward PE 13.9×) is more attractive than peers in the recent pullback, but near-term momentum is negative.
Macro: "Higher-for-longer, no-landing" macro regime: 10-year Treasury yield at highest level since 2002 with biggest monthly gain since 2022; Federal Reserve telegraphing rates stay higher for longer with zero cuts priced at 96%; Iran war driving broad-based inflation higher; September jobs miss but market interpreted as supportive (tech rallied, yields initially eased); US recession odds at 6% (-2.0pp WoW) effectively dismissing near-term recession; Moody's Zandi and Goldman Sachs flagged economic vulnerability to sustained higher rates.